Start › Szpiczak mnogi › Wisconsin › Milwaukee
Badania kliniczne dla Szpiczak mnogi w mieście Milwaukee, WI
21 badań dla Szpiczak mnogi szuka uczestników w ośrodkach w mieście Milwaukee i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RekrutacjaFaza 3
- Research Site, Milwaukee
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RekrutacjaFaza 1/2
- Medical College of Wisconsin, Milwaukee
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RekrutacjaFaza 3
- Medical College Of Wisconsin, Milwaukee
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RekrutacjaFaza 4
- Froedtert Memorial, Milwaukee
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RekrutacjaFaza 1/2
- The Medical College of Wisconsin, Milwaukee
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekrutacjaFaza 2
- Aurora Cancer Care Milwaukee, Milwaukee
- Aurora St. Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- i 4 więcej
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RekrutacjaFaza 3
- Medical College of Wisconsin, Milwaukee
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
RekrutacjaFaza 3
- Medical College of Wisconsin, Milwaukee
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
RekrutacjaFaza 1/2
- Research Site, Milwaukee
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RekrutacjaFaza 3
- Aurora Cancer Care-Milwaukee, Milwaukee
- Ascension Southeast Wisconsin Hospital-Saint Joseph-Milwaukee, Milwaukee
- Ascension Columbia Saint Mary's Hospital-Milwaukee Campus, Milwaukee
- i 13 więcej
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RekrutacjaFaza 1/2
- Research Site, Milwaukee
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
RekrutacjaFaza 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RekrutacjaFaza 2
- MCW-Clinical Cancer Center at Froedtert Hospital Campus, Milwaukee
Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
Rekrutacja
- Medical College of Wisconsin, Milwaukee
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RekrutacjaFaza 3
- Froedtert Memorial Lutheran Hospital, Milwaukee
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
RekrutacjaFaza 2
- Medical College of Wisconsin, Milwaukee
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RekrutacjaFaza 1
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
RekrutacjaFaza 2
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
RekrutacjaFaza 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
Long-term Follow-up Study of Patients Receiving CAR-T Cells
RekrutacjaBadanie obserwacyjne
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RekrutacjaFaza 1
- Froedtert and the Medical College of Wisconsin, Milwaukee
Badania dla Szpiczak mnogi w innych miastach
- New York City, NY60 badań
- Boston, MA42 badań
- Atlanta, GA41 badań
- Houston, TX38 badań
- Durham, NC37 badań
- Nashville, TN32 badań
- Denver, CO27 badań
- Rochester, MN24 badań
- St. Louis, MO24 badań
- Columbus, OH24 badań
- Baldwin Park, CA23 badań
- Chicago, IL22 badań
Inne badania w mieście Milwaukee
- Rak piersi23 badań
- Niedrobnokomórkowy rak płuca22 badań
- Nowotwory (wszystkie typy)22 badań
- Rak płuc21 badań
- Rak prostaty20 badań
- Chłoniak pęcherzykowy19 badań
- Rak trzustki18 badań
- Chłoniak nieziarniczy18 badań
- Rak jajnika17 badań
- Ostra białaczka szpikowa17 badań
- Chłoniak Burkitta16 badań
- Niewydolność serca16 badań
Źródło: ClinicalTrials.gov, dane pobrane 5 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.